This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Intel, McDonald's, CME Group and Gilead Sciences
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $68.22, moving +0.78% from the previous trading session.
Top Stock Reports for JPMorgan, Intel & McDonald's
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), Intel (INTC), and McDonald's (MCD).
Gilead (GILD) Gains 19% YTD: What to Expect in The Second Half?
by Zacks Equity Research
Gilead (GILD) maintains momentum in the year so far on the back of Veklury for the treatment of COVID-19 and the same is expected to continue in the second half.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $68.86, moving +1.37% from the previous trading session.
Gilead's (GILD) Kite Announces Positive Data on Yescarta
by Zacks Equity Research
Gilead (GILD) announces results from the ZUMA-7 study on Yescarta and completes submission of application to the FDA seeking approval of lenacapavir.
Roche's (RHHBY) Actemra Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
The FDA issues an Emergency Use Authorization for Roche's (RHHBY) Actemra for the treatment of COVID-19 in hospitalized adults and pediatric patients.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $67.18 in the latest trading session, marking a +0.8% move from the prior day.
Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients
by Zacks Equity Research
Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.
Gilead (GILD) Inks Deal to Develop Allogeneic Cell Therapies
by Zacks Equity Research
Gilead's (GILD) wholly owned subsidiary Kite signs partnership deal with Shoreline Biosciences to develop novel cell therapies for cancer.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $67.22, marking a -0.16% move from the previous day.
Should You Buy Biotech ETFs Now?
by Neena Mishra
Biotech stocks are rallying this month; can the trend continue?
Cocrystal's (COCP) Antiviral CDI-45205 Effective Against COVID-19
by Zacks Equity Research
Cocrystal (COCP) SARS-CoV-2 3CL protease inhibitor, CDI-45205, found to be effective in treating the original and two other variants of the COVID-19 virus. Shares up.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $68.77 in the latest trading session, marking a -0.75% move from the prior day.
Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day.
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Regeneron, Gilead Sciences, Amgen, Biogen, BioNTech, Repligen and Ovid Therapeutics
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
How Will Biotech ETFs React to These Q1 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
by Zacks Equity Research
FATE reports a wider Q1 loss on increased R&D expenses.
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
Gilead (GILD) Beats on Q1 Earnings, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) reports mixed results for the first quarter as the ongoing pandemic adversely impacted core HIV segment sales.
Gilead Sciences (GILD) Q1 Earnings Beat Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 0.97% and -5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?